Drug Profile
Cabamiquine - Merck Serono
Alternative Names: DDD-107498; DDD498; GTPL9737; M-5717; MM5717; MMV-121Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Medicines for Malaria Venture; University of Dundee
- Developer Merck Serono
- Class Amides; Antimalarials; Fluorinated hydrocarbons; Morpholines; Pyrrolidines; Quinolines; Small molecules
- Mechanism of Action Peptide elongation factor 2 inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Falciparum malaria; Malaria
Most Recent Events
- 28 Nov 2023 Phase-II clinical trials in Falciparum malaria (Combination therapy, In adolescents, In adults) in Kenya, Burkina Faso, Gambia, Zambia (PO) (NCT05974267)
- 03 Aug 2023 Merck KGaA plans a phase II CAPTURE 2 trial for Falciparum malaria (Combination therapy, In adolescents, In adults) in Germany (PO) in August 2023 (PO) (NCT05974267)
- 29 Mar 2023 Phase-II clinical trials in Malaria (Combination therapy, In children, In adolescents, In adults) in Uganda (PO) (NCT05689047) (MERCK KGAA, pipeline, March 2023)